General Information of the Compound
| Compound ID |
CP0048056
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
((1R,4S,5R)-4-(2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methanol
Show/Hide
|
||||||||||||||||||
| Synonyms |
Bicyclic cannabinoids, Pharmos
CB2-selective cannabinoid platform, Pharmos
Cannabinor
HU-308
Oral Cannabinor (pain), Pharmos
PRS-211058
PRS-211096
PRS-211335
PRS-211359
PRS-211375
PRS-211375 (iv, inflammation/autoimmune disease), Pharmos
PRS-211375 (oral, pain), Pharmos
PRS-211375 iv
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C27H42O3
|
||||||||||||||||||
| Molecular Weight |
414.63
|
||||||||||||||||||
| Canonical SMILES |
CCCCCCC(C)(C)c1cc(OC)c([C@H]2C=C(CO)[C@@H]3C[C@H]2C3(C)C)c(OC)c1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
CFMRIVODIXTERW-FDFHNCONSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound